Denna sida på svenska
Loading profile information...

Publications

Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes
Njenda Dt, Aralaguppe Sg, Singh K, Rao R, Sönnerborg A, Sarafianos Sg, et al
The Journal of antimicrobial chemotherapy 2018;73(10):2721-2728

Baseline predictors of antiretroviral treatment failure and lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia
Telele Nf, Kalu Aw, Marrone G, Gebre-selassie S, Fekade D, Tegbaru B, et al
PloS one 2018;13(7):e0200505-

Coreceptor Tropism and Maraviroc Sensitivity of Clonally Derived Ethiopian HIV-1C Strains Using an in-house Phenotypic Assay and Commonly Used Genotypic Methods
Kalu Aw, Telele Nf, Aralaguppe Sg, Gebre-selassie S, Fekade D, Marrone G, et al
Current HIV research 2018;16(2):113-120

Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations
Sörstedt E, Carlander C, Flamholc L, Hejdeman B, Svedhem V, Sönnerborg A, et al
International journal of antimicrobial agents 2018;51(5):733-738

Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes
Neogi U, Singh K, Aralaguppe Sg, Rogers Lc, Njenda Dt, Sarafianos Sg, et al
AIDS (London, England) 2018;32(4):469-476

Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs
Iedea Cohere Cohort Collaborations, Anderegg N, Panayidou K, Abo Y, Alejos B, Althoff Kn, et al
CLINICAL INFECTIOUS DISEASES 2018;66(6):893-903

Human Immunodeficiency Virus Type-1 Elite Controllers Maintain Low Co-Expression of Inhibitory Receptors on CD4+ T Cells
Noyan K, Nguyen S, Betts Mr, Sönnerborg A, Buggert M
Frontiers in immunology 2018;9():19-

Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden
Andersson E, Nordquist A, Esbjörnsson J, Flamholc L, Gisslén M, Hejdeman B, et al
AIDS (London, England) 2018;32(7):877-884

Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease
Buggert M, Nguyen S, Mclane Lm, Steblyanko M, Anikeeva N, Paquin-proulx D, et al
PLoS pathogens 2018;14(4):e1006973-

Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: a comparison of Sanger and high-throughput sequencing
Telele Nf, Kalu Aw, Gebre-selassie S, Fekade D, Abdurahman S, Marrone G, et al
Scientific reports 2018;8(1):7556-

Prophylaxis and treatment of HIV-1 infection in pregnancy - Swedish Recommendations 2017
Navér L, Albert J, Carlander C, Flamholc L, Gisslén M, Karlström O, et al
Infectious diseases (London, England) 2018;50(7):495-506

Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes
Rogers L, Obasa Ae, Jacobs Gb, Sarafianos Sg, Sonnerborg A, Neogi U, et al
FRONTIERS IN MICROBIOLOGY 2018;:1754-

Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia
Carlander C, Wagner P, Van Beirs A, Yilmaz A, Elfgren K, Dillner J, et al
AIDS (London, England) 2018;32(11):1475-1484

Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort
For Cascade Collaboration In Eurocoord, Olson A, Bannert N, Sönnerborg A, De Mendoza C, Price M, et al
AIDS (London, England) 2018;32(2):161-169

Transcriptomics and Targeted Proteomics Analysis to Gain Insights Into the Immune-control Mechanisms of HIV-1 Infected Elite Controllers
Zhang W, Ambikan At, Sperk M, Van Domselaar R, Nowak P, Noyan K, et al
EBioMedicine 2018;27():40-50

A21 HIV-1 sub-subtype F1 outbreak among MSM in Belgium
Vinken L, Fransen K, Pineda-peña Ac, Alexiev I, Balotta C, Debaisieux L, et al
Virus evolution 2017;3(Suppl 1):-

A high rate of HIV-1 acquisition post immigration among migrants in Sweden determined by a CD4 T-cell decline trajectory model
Brännström J, Sönnerborg A, Svedhem V, Neogi U, Marrone G
HIV medicine 2017;18(9):677-684

Antiretroviral treatment for HIV infection: Swedish recommendations 2016
Eriksen J, Albert J, Blaxhult A, Carlander C, Flamholc L, Gisslén M, et al
Infectious diseases (London, England) 2017;49(1):1-34

Assessing cervical intraepithelial neoplasia as an indicator disease for HIV in a low endemic setting: a population-based register study
Carlander C, Marrone G, Brännström J, Yilmaz A, Elfgren K, Sparén P, et al
BJOG : an international journal of obstetrics and gynaecology 2017;124(11):1680-1687

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study
Cohere In Eurocoord And Achiev2e Study Group, Wittkop L, Arsandaux J, Trevino A, Schim Van Der Loeff M, Anderson J, et al
The Journal of antimicrobial chemotherapy 2017;72(10):2869-2878

Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy
Svärd J, Mugusi S, Mloka D, Neogi U, Meini G, Mugusi F, et al
PloS one 2017;12(6):e0178942-

Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients
Häggblom A, Santacatterina M, Neogi U, Gisslen M, Hejdeman B, Flamholc L, et al
PloS one 2017;12(7):e0180140-

Evaluating the Impact of Functional Genetic Variation on HIV-1 Control
Mclaren Pj, Pulit Sl, Gurdasani D, Bartha I, Shea Pr, Pomilla C, et al
The Journal of infectious diseases 2017;216(9):1063-1069

Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa
Aralaguppe Sg, Winner D, Singh K, Sarafianos Sg, Quiñones-mateu Me, Sönnerborg A, et al
Journal of medical virology 2017;89(1):106-111

Letter to the editor: Pre-exposure prophylaxis for HIV in Europe: The need for resistance surveillance
Van Tienen C, Van De Vijver D, Noori T, Sönnerborg A, Boucher C
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2017;22(11):-

Monophylogenetic HIV-1C epidemic in Ethiopia is dominated by CCR5-tropic viruses-an analysis of a prospective country-wide cohort
Kalu Aw, Telele Nf, Gebreselasie S, Fekade D, Abdurahman S, Marrone G, et al
BMC infectious diseases 2017;17(1):37-

Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals
Tauriainen J, Scharf L, Frederiksen J, Naji A, Ljunggren Hg, Sönnerborg A, et al
Scientific reports 2017;7():40354-

PhyloGeoTool: interactively exploring large phylogenies in an epidemiological context
Eucohiv Study Group, Libin P, Vanden Eynden E, Incardona F, Nowé A, Bezenchek A, et al
Bioinformatics (Oxford, England) 2017;33(24):3993-3995

Prediction of coreceptor usage by five bioinformatics tools in a large Ethiopian HIV-1 subtype C cohort
Kalu Aw, Telele Nf, Gebreselasie S, Fekade D, Abdurahman S, Marrone G, et al
PloS one 2017;12(8):e0182384-

Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy
Zhang W, Morshed Mm, Noyan K, Russom A, Sönnerborg A, Neogi U
Scientific reports 2017;7(1):666-

Recent increased identification and transmission of HIV-1 unique recombinant forms in Sweden
Neogi U, Siddik Ab, Kalaghatgi P, Gisslén M, Bratt G, Marrone G, et al
Scientific reports 2017;7(1):6371-

Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers
Vesterbacka J, Rivera J, Noyan K, Parera M, Neogi U, Calle M, et al
Scientific reports 2017;7(1):6269-

Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90-90-90 continuum of HIV care targets
Gisslén M, Svedhem V, Lindborg L, Flamholc L, Norrgren H, Wendahl S, et al
HIV medicine 2017;18(4):305-307

The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges
European Hiv Continuum Of Care Working Group, Gourlay A, Noori T, Pharris A, Axelsson M, Costagliola D, et al
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017;64(12):1644-1656

Deficiencies in the health care system contribute to a high rate of late HIV diagnosis in Sweden
Brännström J, Svedhem Johansson V, Marrone G, Wendahl S, Yilmaz A, Blaxhult A, et al
HIV medicine 2016;17(6):425-35

Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries
Neogi U, Häggblom A, Singh K, Rogers Lc, Rao Sd, Amogne W, et al
The Journal of antimicrobial chemotherapy 2016;71(2):367-71

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
Tenores Study Grp, Gregson J, Tang M, Ndembi N, Hamers Rl, Rhee Sy, et al
LANCET INFECTIOUS DISEASES 2016;16(5):565-575

Gut Microbiota Linked to Sexual Preference and HIV Infection
Noguera-julian M, Rocafort M, Guillén Y, Rivera J, Casadellà M, Nowak P, et al
EBioMedicine 2016;5():135-46

HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries
Spread/esar Programme, Esbjörnsson J, Mild M, Audelin A, Fonager J, Skar H, et al
Virus evolution 2016;2(1):vew010-

Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden
Carlander C, Wagner P, Svedhem V, Elfgren K, Westling K, Sönnerborg A, et al
International journal of cancer 2016;139(7):1471-9

Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam
Cuong Dd, Sönnerborg A, Van Tam V, El-khatib Z, Santacatterina M, Marrone G, et al
BMC infectious diseases 2016;16(1):759-

Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia
Pediat Aids-defining Canc Project, Tanser F, Vinikoor M, Macete E, Wood R, Stinson K, et al
CLINICAL INFECTIOUS DISEASES 2016;63(9):1245-1253

Multiplexed next-generation sequencing and de novo assembly to obtain near full-length HIV-1 genome from plasma virus
Aralaguppe Sg, Siddik Ab, Manickam A, Ambikan At, Kumar Mm, Fernandes Sj, et al
Journal of virological methods 2016;236():98-104

Mutational Heterogeneity in p6 Gag Late Assembly (L) Domains in HIV-1 Subtype C Viruses from South Africa
Neogi U, Engelbrecht S, Claassen M, Jacobs Gb, Van Zyl G, Preiser W, et al
AIDS research and human retroviruses 2016;32(1):80-4

Phylogenetic Analysis of Ethiopian HIV-1 Subtype C Near Full-Length Genomes Reveals High Intrasubtype Diversity and a Strong Geographical Cluster
Amogne W, Bontell I, Grossmann S, Aderaye G, Lindquist L, Sönnerborg A, et al
AIDS research and human retroviruses 2016;32(5):471-4

Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy
Gaines H, Albert J, Axelsson M, Berglund T, Gisslén M, Sönnerborg A, et al
Infectious diseases (London, England) 2016;48(2):93-8

Symptomatic Patients without Epidemiological Indicators of HIV Have a High Risk of Missed Diagnosis: A Multi-Centre Cross Sectional Study
Brännström J, Svedhem V, Marrone G, Andersson Ö, Azimi F, Blaxhult A, et al
PloS one 2016;11(9):e0162503-

The global spread of HIV-1 subtype B epidemic
Spread Program, Magiorkinis G, Angelis K, Mamais I, Katzourakis A, Hatzakis A, et al
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2016;46():169-179

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
Spread Program, Hofstra Lm, Sauvageot N, Albert J, Alexiev I, Garcia F, et al
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016;62(5):655-663

Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels
Sörstedt E, Nilsson S, Blaxhult A, Gisslén M, Flamholc L, Sönnerborg A, et al
BMC infectious diseases 2016;16():305-

Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden
Häggblom A, Svedhem V, Singh K, Sönnerborg A, Neogi U
The lancet. HIV 2016;3(4):e166-74

Arming of MAIT Cell Cytolytic Antimicrobial Activity Is Induced by IL-7 and Defective in HIV-1 Infection
Leeansyah E, Svärd J, Dias J, Buggert M, Nyström J, Quigley Mf, et al
PLoS pathogens 2015;11(8):e1005072-

Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial
Amogne W, Aderaye G, Habtewold A, Yimer G, Makonnen E, Worku A, et al
PloS one 2015;10(5):e0122587-

Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data
Etravirine Cohort Study Group, Vingerhoets J, Calvez V, Flandre P, Marcelin Ag, Ceccherini-silberstein F, et al
HIV medicine 2015;16(5):297-306

Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia
Angelis K, Albert J, Mamais I, Magiorkinis G, Hatzakis A, Hamouda O, et al
The Journal of infectious diseases 2015;211(11):1735-44

Gut microbiota diversity predicts immune status in HIV-1 infection
Nowak P, Troseid M, Avershina E, Barqasho B, Neogi U, Holm K, et al
AIDS (London, England) 2015;29(18):2409-18

Minor viral population with drug-resistant mutation and risk of persistent low-level viremia or 'blips' in HIV-1 subtype C: Erratum (vol 28, pg 2635, 2014)
Neogi U, Sonnerborg A
AIDS 2015;29(2):251-251

Multidimensional Clusters of CD4+ T Cell Dysfunction Are Primarily Associated with the CD4/CD8 Ratio in Chronic HIV Infection
Frederiksen J, Buggert M, Noyan K, Nowak P, Sönnerborg A, Lund O, et al
PloS one 2015;10(9):e0137635-

Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART
Stiksrud B, Nowak P, Nwosu Fc, Kvale D, Thalme A, Sonnerborg A, et al
Journal of acquired immune deficiency syndromes (1999) 2015;70(4):329-37

Role of translocated bacterial flagellin in monocyte activation among individuals with chronic HIV-1 infection
Svärd J, Paquin-proulx D, Buggert M, Noyan K, Barqasho B, Sönnerborg A, et al
Clinical immunology (Orlando, Fla.) 2015;161(2):180-9

Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries
Ekici H, Rao Sd, Sönnerborg A, Ramprasad Vl, Gupta R, Neogi U
The Journal of antimicrobial chemotherapy 2014;69(12):3349-55

Decreased phenotypic susceptibility to etravirine in patients with predicted genotypic sensitivity
Agneskog E, Nowak P, Maijgren Steffensson C, Casadellà M, Noguera-julian M, Paredes R, et al
PloS one 2014;9(7):e101508-

Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors
Singh K, Flores Ja, Kirby Ka, Neogi U, Sonnerborg A, Hachiya A, et al
Viruses 2014;6(9):3535-62

High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort
Stenkvist J, Weiland O, Sönnerborg A, Blaxhult A, Falconer K
Scandinavian journal of infectious diseases 2014;46(9):624-32

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe
Spread Programme, Frentz D, Van De Vijver Da, Abecasis Ab, Albert J, Hamouda O, et al
BMC infectious diseases 2014;14():407-

Minority drug-resistant HIV-1 variants in treatment naïve East-African and Caucasian patients detected by allele-specific real-time PCR
Ekici H, Amogne W, Aderaye G, Lindquist L, Sönnerborg A, Abdurahman S
PloS one 2014;9(10):e111042-

Minor viral population with drug-resistant mutation and risk of persistent low-level viremia or 'blips' in HIV-1 subtype C
Neogi U, Sonnerborg A
AIDS (London, England) 2014;28(17):2635-6

Multiparametric bioinformatics distinguish the CD4/CD8 ratio as a suitable laboratory predictor of combined T cell pathogenesis in HIV infection
Buggert M, Frederiksen J, Noyan K, Svärd J, Barqasho B, Sönnerborg A, et al
Journal of immunology (Baltimore, Md. : 1950) 2014;192(5):2099-108

Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients
Neogi U, Rao Sd, Bontell I, Verheyen J, Rao Vr, Gore Sc, et al
AIDS (London, England) 2014;28(15):2319-22

Occasional spontaneous clearance of chronic hepatitis C virus in HIV-infected individuals
Stenkvist J, Nyström J, Falconer K, Sönnerborg A, Weiland O
Journal of hepatology 2014;61(4):957-61

On the usefulness of circulating bacterial 16S rDNA as a marker of microbial translocation in HIV-1-infected patients
Svärd J, Sönnerborg A, Vondracek M, Mölling P, Nowak P
Journal of acquired immune deficiency syndromes (1999) 2014;66(4):e87-9

On the Usefulness of Circulating Bacterial 16S rDNA as a Marker of Microbial Translocation in HIV-1-Infected Patients
Svard J, Sonnerborg A, Vondracek M, Molling P, Nowak P
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 2014;66(4):E87-E89

Pattern of microbial translocation in patients living with HIV-1 from Vietnam, Ethiopia and Sweden
Abdurahman S, Barqasho B, Nowak P, Cuong Do D, Amogné W, Larsson M, et al
Journal of the International AIDS Society 2014;17():18841-

Patterns of transmitted HIV drug resistance in Europe vary by risk group
Spread Programme, Frentz D, Van De Vijver D, Abecasis A, Albert J, Hamouda O, et al
PloS one 2014;9(4):e94495-

Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013
Navér L, Albert J, Böttiger Y, Carlander C, Flamholc L, Gisslén M, et al
Scandinavian journal of infectious diseases 2014;46(6):401-11

Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy
Albert J, Berglund T, Gisslén M, Gröön P, Sönnerborg A, Tegnell A, et al
Scandinavian journal of infectious diseases 2014;46(10):673-7

T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection
Buggert M, Tauriainen J, Yamamoto T, Frederiksen J, Ivarsson Ma, Michaëlsson J, et al
PLoS pathogens 2014;10(7):e1004251-

Temporal trends in the Swedish HIV-1 epidemic: increase in non-B subtypes and recombinant forms over three decades
Neogi U, Häggblom A, Santacatterina M, Bratt G, Gisslén M, Albert J, et al
PloS one 2014;9(6):e99390-

Time on drug analysis based on real life data
Schülter E, Kaiser R, Zazzi M, Sönnerborg A, Camacho R, Verheyen J
Journal of the International AIDS Society 2014;17(4 Suppl 3):19790-

Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection
Leeansyah E, Ganesh A, Quigley Mf, Sönnerborg A, Andersson J, Hunt Pw, et al
Blood 2013;121(7):1124-35

AIDS and HIV Infection after Thirty Years
Ippolito G, Levy Ja, Sonnerborg A, Mugusi F, Dianzani F
AIDS research and treatment 2013;2013():731983-

Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response
Vercauteren J, Beheydt G, Prosperi M, Libin P, Imbrechts S, Camacho R, et al
PloS one 2013;8(4):e61436-

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe
Sehere Collaboration In Chain, De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, et al
The Journal of infectious diseases 2013;207(8):1216-20

Evaluation of etravirine resistance in clinical samples by a simple phenotypic test
Agneskog E, Nowak P, Källander Cf, Sönnerborg A
Journal of medical virology 2013;85(4):703-8

Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys
Andersson E, Shao W, Bontell I, Cham F, Cuong Do D, Wondwossen A, et al
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2013;18():125-31

Evolution of fibrosis during HCV recurrence after liver transplantation - influence of IL-28B SNP and response to peg-IFN and ribavirin treatment
Ackefors M, Nystrom J, Wernerson A, Gjertsen H, Sonnerborg A, Weiland O
JOURNAL OF VIRAL HEPATITIS 2013;20(11):770-8

Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study)
Sullivan Ak, Raben D, Reekie J, Rayment M, Mocroft A, Esser S, et al
PloS one 2013;8(1):e52845-

HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism
Stenkvist J, Sönnerborg A, Weiland O
Journal of viral hepatitis 2013;20(3):193-9

HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure
Virolab And Euresist Projects, Sangeda Rz, Theys K, Beheydt G, Rhee Sy, Deforche K, et al
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2013;19():349-60

HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
Abecasis Ab, Wensing Am, Paraskevis D, Vercauteren J, Theys K, Van De Vijver Da, et al
Retrovirology 2013;10():7-

HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir
Theys K, Vercauteren J, Snoeck J, Zazzi M, Camacho Rj, Torti C, et al
Antimicrobial agents and chemotherapy 2013;57(2):1053-6

HIV care in the Swedish-Danish HIV cohort 1995-2010, closing the gaps
Helleberg M, Häggblom A, Sönnerborg A, Obel N
PloS one 2013;8(8):e72257-

Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals
Neogi U, Shet A, Sahoo Pn, Bontell I, Ekstrand Ml, Banerjea Ac, et al
Journal of the International AIDS Society 2013;16():18472-

Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy
Vesterbacka J, Nowak P, Barqasho B, Abdurahman S, Nyström J, Nilsson S, et al
PloS one 2013;8(1):e55038-

Limited cross-border infections in patients newly diagnosed with HIV in Europe
Spread Programme, Frentz D, Wensing Am, Albert J, Paraskevis D, Abecasis Ab, et al
Retrovirology 2013;10():36-

Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection
Jansen K, Sönnerborg A, Brockmeyer N, Thalme A, Svedhem V, Dupke S, et al
AIDS research and human retroviruses 2013;29(3):564-73

Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection
Jansen K, Sönnerborg A, Brockmeyer N, Thalme A, Svedhem V, Dupke S, et al
AIDS research and human retroviruses 2013;29(3):564-73

Long-term efficacy of first line antiretroviral therapy in Indian HIV-1 infected patients: a longitudinal cohort study
Neogi U, Heylen E, Shet A, Chandy S, Shamsunder R, Sönnerborg A, et al
PloS one 2013;8(1):e55421-

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial
Andersson Lm, Vesterbacka J, Blaxhult A, Flamholc L, Nilsson S, Ormaasen V, et al
Scandinavian journal of infectious diseases 2013;45(7):543-51

Molecular dating of HIV-1 subtype C from Bangladesh
Bontell I, Sarker Ms, Rahman M, Afrad Mh, Sönnerborg A, Azim T
PloS one 2013;8(11):e79193-

Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs
Gupta Rk, Wainberg Ma, Brun-vezinet F, Gatell Jm, Albert J, Sönnerborg A, et al
The Journal of infectious diseases 2013;207 Suppl 2():S101-6

Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort
Bartha I, Assel M, Sloot Pm, Zazzi M, Torti C, Schülter E, et al
BMC infectious diseases 2013;13():537-

Trends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011
Bontell I, Häggblom A, Bratt G, Albert J, Sönnerborg A
PloS one 2013;8(3):e59337-

Characterization of HIV-specific CD4+ T cell responses against peptides selected with broad population and pathogen coverage
Buggert M, Norström Mm, Czarnecki C, Tupin E, Luo M, Gyllensten K, et al
PloS one 2012;7(7):e39874-

Efficacy of Antiretroviral Therapy Switch in HIV-Infected Patients: A 10-Year Analysis of the EuResist Cohort
Euresist Network Study Grp, Oette M, Schulter E, Rosen-zvi M, Peres Y, Zazzi M, et al
INTERVIROLOGY 2012;55(2):160-6

Higher Prevalence of Predicted X4-Tropic Strains in Perinatally Infected Older Children With HIV-1 Subtype C in India
Neogi U, Sahoo Pn, Arumugam K, Sonnerborg A, De Costa A, Shet A
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 2012;59(4):347-53

Impact of HMGB1/TLR Ligand Complexes on HIV-1 Replication: Possible Role for Flagellin during HIV-1 Infection
Nowak P, Abdurahman S, Lindkvist A, Troseid M, Sönnerborg A
International journal of microbiology 2012;2012():263836-

Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010
Karlsson A, Björkman P, Bratt G, Ekvall H, Gisslén M, Sönnerborg A, et al
PloS one 2012;7(3):e33484-

Molecular epidemiology of HIV-1 subtypes in India: origin and evolutionary history of the predominant subtype C
Neogi U, Bontell I, Shet A, De Costa A, Gupta S, Diwan V, et al
PloS one 2012;7(6):e39819-

Monitoring the efficacy of antiretroviral therapy by a simple reverse transcriptase assay in HIV-infected adults in rural Vietnam
Cuong Dd, Agneskog E, Chuc Ntk, Santacafferina M, Sonnerborg A, Larsson M
FUTURE VIROLOGY 2012;7(9):923-931

Optimizing background therapy in treatment-experienced HIV-1 patients by rules-based algorithms and bioinformatics
Svard J, Sonnerborg A
FUTURE VIROLOGY 2012;7(8):749-757

Predicting Response to Antiretroviral Treatment by Machine Learning: The EuResist Project
Zazzi M, Incardona F, Rosen-zvi M, Prosperi M, Lengauer T, Altmann A, et al
INTERVIROLOGY 2012;55(2):123-7

Survival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern Vietnam
Cuong Dd, Thorson A, Sonnerborg A, Hoa Np, Nguyen Tkc, Phuc Hd, et al
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2012;44(3):201-8

Transmitted drug resistance and phylogenetic analysis of HIV CRF01_AE in Northern Vietnam
Bontell I, Cuong Dd, Agneskog E, Diwan V, Larsson M, Sonnerborg A
INFECTION GENETICS AND EVOLUTION 2012;12(2):448-52

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients
Spread-programme, Theys K, Deforche K, Vercauteren J, Libin P, Van De Vijver Da, et al
Retrovirology 2012;9():81-

Use of InfCare HIV to identify and characterize suboptimally treated HIV patients at a Danish HIV clinic: A cross-sectional cohort study
Dalgaard Ls, Sogaard Os, Jensen-fangel S, Larsen Cs, Sonnerborg A, Ostergaard L
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2012;44(2):108-14

Bilirubin-A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy
Rekic D, Clewe O, Roshammar D, Flamholc L, Sonnerborg A, Ormaasen V, et al
AAPS JOURNAL 2011;13(4):598-605

Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study
Sehere Consortium, Prosperi Mcf, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, et al
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 2011;66(8):1886-96

European guidelines on the clinical management of HIV-1 tropism testing
European Consensus Grp Clinical, Vandekerckhove Lpr, Wensing Amj, Kaiser R, Brun-vezinet F, Clotet B, et al
LANCET INFECTIOUS DISEASES 2011;11(5):394-407

European Recommendations for the Clinical Use of HIV Drug Resistance Testing: 2011 Update
European Hiv Drug Resistance Guide, Vandamme Am, Camacho Rj, Ceccherini-silberstein F, De Luca A, Palmisano L, et al
AIDS REVIEWS 2011;13(2):77-108

High Mobility Group Box Protein-1 in HIV-1 Infection: Connecting Microbial Translocation, Cell Death and Immune Activation
Troseid M, Sonnerborg A, Nowak P
CURRENT HIV RESEARCH 2011;9(1):6-10

HIV-1 mutational pathways under multidrug therapy
Lawyer G, Altmann A, Thielen A, Zazzi M, Sönnerborg A, Lengauer T
AIDS research and therapy 2011;8():26-

Late presentation of HIV infection: a consensus definition
European Late Presenter Consensus, Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, et al
HIV MEDICINE 2011;12(1):61-4

Overcoming obstacles to late presentation for HIV infection in Europe
Lazarus Jv, Jurgens R, Weait M, Phillips A, Hows J, Gatell J, et al
HIV MEDICINE 2011;12(4):246-9

Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study)
Zazzi M, Kaiser R, Sonnerborg A, Struck D, Altmann A, Prosperi M, et al
HIV MEDICINE 2011;12(4):211-8

Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2010
Naver L, Albert J, Belfrage E, Flamholc L, Gisslen M, Gyllensten K, et al
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2011;43(6-7):411-23

Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV
Mellberg T, Gonzalez Vd, Lindkvist A, Edén A, Sönnerborg A, Sandberg Jk, et al
AIDS research and therapy 2011;8():21-

Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models
Virolab Study Grp, Euresist Study Grp, Prosperi Mcf, Rosen-zvi M, Altmann A, Zazzi M, et al
PLOS ONE 2010;5(10):e13753-

Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Naive HIV-1-Infected Patients
Eden A, Andersson Lm, Andersson O, Flamholc L, Josephson F, Nilsson S, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 2010;26(5):533-40

Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy
Troseid M, Nowak P, Nystrom J, Lindkvist A, Abdurahman S, Sonnerborg A
AIDS 2010;24(11):1733-7

Implications of the release of high-mobility group box 1 protein from dying cells during human immunodeficiency virus type 1 infection in vitro
Barqasho B, Nowak P, Abdurahman S, Walther-jallow L, Sonnerborg A
JOURNAL OF GENERAL VIROLOGY 2010;:1800-9

InfCare HIV - A health-informatic tool for improvement of HIV clinical care and research in Africa
Sonnerborg A
TROPICAL MEDICINE & INTERNATIONAL HEALTH 2010;15(8):S12-S12

Only Slight Impact of Predicted Replicative Capacity for Therapy Response Prediction
Weisser H, Altmann A, Sierra S, Incardona F, Struck D, Sonnerborg A, et al
PLOS ONE 2010;5(2):e9044-

Pairwise comparison of genotypic tropism prediction between 1 reference centre and 10 European laboratories
Sierra S, Balduin M, Zazzi M, Sonnerborg A, Geretti Am, Vandekerckhove I, et al
ANTIVIRAL THERAPY 2010;15(4):A22-A22

Pairwise comparison of genotypic tropism prediction between 1 reference centre and 10 European laboratories
Sierra S, Balduin M, Zazzi M, Sonnerborg A, Geretti Am, Vandekerckhove I, et al
ANTIVIRAL THERAPY 2010;:A22-A22

Prevalence and patterns of raltegravir resistance in treated patients in Europe
Coronet Study Grp Collaboration, Geretti Am, Fearnhill E, Ceccherini-silberstein F, Sonnerborg A, Soriano V, et al
ANTIVIRAL THERAPY 2010;15(4):A62-A62

Prevalence and patterns of raltegravir resistance in treated patients in Europe
Coronet Study Grp & Collaboration, Geretti Am, Fearnhill E, Ceccherini-silberstein F, Sonnerborg A, Soriano V, et al
ANTIVIRAL THERAPY 2010;:A62-A62

The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-na < ve HIV-1 infected patients
Josephson F, Andersson Mch, Flamholc L, Gisslen M, Hagberg L, Ormaasen V, et al
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2010;66(4):349-57

Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype
Altmann A, Sing T, Vermeiren H, Winters B, Van Craenenbroeck E, Van Der Borght K, et al
ANTIVIRAL THERAPY 2009;14(2):273-83

Difference in drug resistance patterns between minor HIV-1 populations in cerebrospinal fluid and plasma
Bergroth T, Ekici H, Gisslen M, Hagberg L, Sonnerborg A
HIV MEDICINE 2009;10(2):111-5

Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment
Euresist Virolab Study Grp, Prosperi Mcf, Altmann A, Rosen-zvi M, Aharoni E, Gabor B, et al
ANTIVIRAL THERAPY 2009;14(3):433-42

Kinetics of plasma cytokines and chemokines during primary HIV-1 infection and after analytical treatment interruption
Quest Study Grp, Barqasho B, Nowak P, Tjernlund A, Kinloch S, Goh Le, et al
HIV MEDICINE 2009;10(2):94-102

Predicting the Response to Combination Antiretroviral Therapy: Retrospective Validation of geno2pheno-THEO on a Large Clinical Database
Altmann A, Daumer M, Beerenwinkel N, Peres Y, Schulter E, Buch J, et al
JOURNAL OF INFECTIOUS DISEASES 2009;199(7):999-1006

Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study
Lindkvist A, Edén A, Norström Mm, Gonzalez Vd, Nilsson S, Svennerholm B, et al
AIDS research and therapy 2009;6():15-

Selection of Drug-Resistant HIV-1 During the Early Phase of Viral Decay Is Uncommon in Treatment-Naive Patients Initiated on a Three- or Four-Drug Antiretroviral Regimen Including Lamivudine
Bergroth T, Ekici H, Gisslen M, Kinloch-de Loes S, Goh Le, Freedman A, et al
JOURNAL OF MEDICAL VIROLOGY 2009;81(1):1-8

Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection
Moll M, Kuylenstierna C, Gonzalez Vd, Andersson Sk, Bosnjak L, Sonnerborg A, et al
EUROPEAN JOURNAL OF IMMUNOLOGY 2009;39(3):902-11

Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe
Spread Programme, Vercauteren J, Wensing Amj, Van De Vijver Damc, Albert J, Balotta C, et al
JOURNAL OF INFECTIOUS DISEASES 2009;200(10):1503-8

Treatment of HIV infection: Swedish recommendations 2009
Josephson F, Albert J, Flamholc L, Gisslen M, Karlstrom O, Moberg L, et al
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2009;41(11-12):788-807

Comparison of Classifier Fusion Methods for Predicting Response to Anti HIV-1 Therapy
Altmann A, Rosen-zvi M, Prosperi M, Aharoni E, Neuvirth H, Schulter E, et al
PLOS ONE 2008;3(10):e3470-

CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4 beta-hydroxycholesterol levels
Josephson F, Bertilsson L, Bottiger Y, Flamholc L, Gisslen M, Ormaasen V, et al
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2008;64(8):775-81

Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2007
Naver L, Bohlin Ab, Albert J, Flamholc L, Gisslen M, Gyllensten K, et al
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2008;40(6-7):451-61

Selecting anti-HIV therapies based on a variety of genomic and clinical factors
Rosen-zvi M, Altmann A, Prosperi M, Aharoni E, Neuvirth H, Sonnerborg A, et al
BIOINFORMATICS 2008;24(13):i399-406

Transmission of drug-resistant HIV-1 in Europe remains limited to single classes
Spread Programme, Wensing Amj, Vercauteren J, Van De Vijver Da, Albert J, Asjo B, et al
AIDS 2008;22(5):625-35

Treatment of chronic hepatitis B infection: An update of Swedish recommendations
Lindh M, Uhnoo I, Blackberg J, Duberg As, Friman S, Fischler B, et al
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2008;40(6-7):436-50

Virological Characterization of Dual HIV-1/HIV-2 Seropositivity and Infections in Southern Ghana
Sagoe K, Mingle J, Affram R, Britton S, Dzokoto A, Sonnerborg A
Ghana medical journal 2008;42(1):16-21

Antiretroviral treatment of HIV infection: Swedish recommendations 2007
Josephson F, Albert J, Flamholc L, Gisslen M, Karlstrom O, Lindgren Sr, et al
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2007;39(6-7):486-507

A structural equation modeling approach to the concepts of adherence and readiness in antiretroviral treatment
Sodergard B, Hofer S, Halvarsson M, Sonnerborg A, Tully Mp, Lindblad Ak
PATIENT EDUCATION AND COUNSELING 2007;67(1-2):108-16

Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection
Nilsson J, Kinloch-de-loes S, Granath A, Sonnerborg A, Goh Le, Andersson J
AIDS 2007;21(5):565-74

Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy - Reply
Karlstrom O, Josephson F, Sonnerborg A
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 2007;46(1):118-119

Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy
Karlstrom O, Josephson F, Sonnerborg A
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 2007;44(4):417-22

Elevated plasma levels of high mobility group box protein 1 in patients with HIV-1 infection
Nowak P, Barqasho B, Sonnerborg A
AIDS 2007;21(7):869-71

Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure
Svedhem V, Bergroth T, Lidman K, Sonnerborg A
HIV MEDICINE 2007;8(8):504-10

Adherence to treatment in Swedish HIV-infected patients
Sodergard B, Halvarsson M, Tully Mp, Mindouri S, Nordstrom Ml, Lindback S, et al
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS 2006;31(6):605-16

Antiretroviral treatment of HIV infection: Swedish recommendations 2005
Swedish Consensus Grp, Gisslen M, Ahlqvist-rastad J, Albert J, Blaxhult A, Hamberg Ak, et al
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2006;38(2):86-103

Assessing and achieving readiness to initiate HIV medication
Nordqvist O, Sodergard B, Tully Mp, Sonnerborg A, Lindblad Ak
PATIENT EDUCATION AND COUNSELING 2006;62(1):21-30

Differences in adherence and motivation to HIV therapy - two independent assessments in 1998 and 2002
Sodergard B, Halvarsson M, Lindback S, Sonnerborg A, Tully Mp, Lindblad Ak
PHARMACY WORLD & SCIENCE 2006;28(4):248-56

Early induction of leukemia inhibitor factor (LIF) in acute HIV-1 infection
Tjernlund A, Barqasho B, Nowak P, Kinloch S, Thorborn D, Perrin L, et al
AIDS 2006;20(1):11-9

Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients
Karlstrom O, Stahle L, Perrin L, Tegude H, Sonnerborg A
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2006;38(5):371-4

HMGB1 activates replication of latent HIV-1 in a monocytic cell-line, but inhibits HIV-1 replication in primary macrophages
Nowak P, Barqasho B, Treutiger Cj, Harris He, Tracey Kj, Andersson J, et al
CYTOKINE 2006;34(1-2):17-23

Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz
Wang J, Sonnerborg A, Rane A, Josephson F, Lundgren S, Stahle L, et al
PHARMACOGENETICS AND GENOMICS 2006;16(3):191-8

Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR
Bergroth T, Sonnerborg A, Yun Zb
JOURNAL OF VIROLOGICAL METHODS 2005;127(1):100-7

Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir
Svedhem V, Lindkvist A, Bergroth T, Knut L, Sonnerborg A
JOURNAL OF MEDICAL VIROLOGY 2005;76(4):447-51

Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection
Quest Study Grp, Kinloch-de Loes S, Hoen B, Smith De, Autran B, Lampe Fc, et al
JOURNAL OF INFECTIOUS DISEASES 2005;192(4):607-17

Efavirenz plasma concentrations in HIV-infected patients - Inter- and intraindividual variability and clinical effects
Stahle L, Moberg L, Svensson Jo, Sonnerborg A
THERAPEUTIC DRUG MONITORING 2004;26(3):267-70

Expansion of CD7(low) and CD7(negative) CD8 T-cell effector subsets in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment
Aandahl Em, Quigley Mf, Moretto Wj, Moll M, Gonzalez Vd, Sonnerborg A, et al
BLOOD 2004;104(12):3672-8

Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection
De Milito A, Nilsson A, Titanji K, Thorstensson R, Reizenstein E, Narita M, et al
BLOOD 2004;103(6):2180-6

Updated European recommendations for the clinical use of HIV drug resistance testing
Vandamme Am, Sonnerborg A, Ait-khaled M, Albert J, Asjo B, Bacheler L, et al
ANTIVIRAL THERAPY 2004;9(6):829-48

Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations
Sweedish Consensus Grp, Sandstrom E, Uhnoo I, Ahlqvist-rastad J, Bratt G, Berglund T, et al
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2003;35(3):155-67

Follow-up of antiretroviral treatment in liver transplant recipients with primary and chronic HIV type 1 infection
Nowak P, Schvarcz R, Ericzon Bg, Flamholc L, Sonnerborg A
AIDS RESEARCH AND HUMAN RETROVIRUSES 2003;19(1):13-9

Inter-laboratory comparison of HCV-RNA assay results: Implications for multi-centre research
European Paediat Hepatitis C Virus, Pembrey L, Newell Ml, Tovo Pa, Van Drimmelen H, Quinti I, et al
JOURNAL OF MEDICAL VIROLOGY 2003;69(2):195-201

Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter- and cell-specific manner
Naghavi Mh, Nowak P, Andersson J, Sonnerborg A, Yang H, Tracey Kj, et al
VIROLOGY 2003;314(1):179-89

Low frequency of plasma nerve-growth factor detection is associated with death of memory B lymphocytes in HIV-1 infection
Titanji K, Nilsson A, Morch C, Samuelsson A, Sonnerborg A, Grutzmeier S, et al
CLINICAL AND EXPERIMENTAL IMMUNOLOGY 2003;132(2):297-303

Painful and non-painful neuropathy in HIV-infected patients: an analysis of somatosensory nerve function
Martin C, Solders G, Sonnerborg A, Hansson P
EUROPEAN JOURNAL OF PAIN-LONDON 2003;7(1):23-31

Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects (vol 127, pg 486, 2002)
De Milito A, Aleman S, Marenzi R, Sonnerborg A, Fuchs D, Zazzi M, et al
CLINICAL AND EXPERIMENTAL IMMUNOLOGY 2003;134(1):167-167

Suppression of leukemia inhibitor factor in lymphoid tissue in primary HIV infection: absence of HIV replication in gp130-positive cells
Tjernlund A, Fleener Z, Behbahani H, Connick E, Sonnerborg A, Brostrom C, et al
AIDS 2003;17(9):1303-10

Use of genotypic assays for the detection of antiretroviral resistance: a legal proceeding, Rome, 22-23 April 2002 - Guest editor introduction
Sonnerborg A
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2003;:5-

Use of HIV-1 reverse transcriptase recovered from human plasma for phenotypic drug susceptibility testing
Shao Xw, Malmsten A, Lennerstrand J, Sonnerborg A, Unge T, Gronowitz Js, et al
AIDS 2003;17(10):1463-71

Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection
Lore K, Sonnerborg A, Brostrom C, Goh Le, Perrin L, Mcdade H, et al
AIDS 2002;16(5):683-92

Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy
Aleman S, Soderbarg K, Visco-comandini U, Sitbon G, Sonnerborg A
AIDS 2002;16(7):1039-44

Level and pattern of HIV-1-RNA viral load over age: differences between girls and boys?
European Collaborative Study, Giaquinto C, Rampon O, Giacomet V, Rossi Ad, Grosch-worner I, et al
AIDS 2002;16(1):97-104

Low levels of perforin expression in CD8(+) T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection
Andersson J, Kinloch S, Sonnerborg A, Nilsson J, Fehniger Te, Spetz Al, et al
JOURNAL OF INFECTIOUS DISEASES 2002;185(9):1355-8

Monophyletic HIV type 1 CRF02-AG in a nosocomial outbreak in Benghazi, Libya
Libya Project Task Force, Visco-comandini U, Cappiello G, Liuzzi G, Tozzi V, Anzidei G, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 2002;18(10):727-32

Persistence of earlier HIV-1 drug resistance mutations at new treatment failure
Svedhem V, Lindkvist A, Lidman K, Sonnerborg A
JOURNAL OF MEDICAL VIROLOGY 2002;68(4):473-8

Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects
De Milito A, Aleman S, Marenzi R, Sonnerborg A, Fuchs D, Zazzi M, et al
CLINICAL AND EXPERIMENTAL IMMUNOLOGY 2002;127(3):486-94

Quantification of human immunodeficiency virus type I proviral DNA by the TaqMan real-time PCR assay
Yun Zb, Fredriksson E, Sonnerborg A
JOURNAL OF CLINICAL MICROBIOLOGY 2002;40(10):3883-4

Special issue: NOBEL SYMPOSIUM 119 - Global HIV Therapeutics - HIV Vaccines Nobel Forum, Karolinska Institutet, June 7-9, 2001 - Foreword
Lijestrom P, Andersson J, Sonnerborg A
VACCINE 2002;20(15):1895-1895

[Swedish guidelines for antiretroviral treatment of HIV. Good compliance is crucial for a good result]
Gisslén M, Sönnerborg A
Lakartidningen 2002;99(43):4263-6

The selection and evolution of viral quasispecies in HIV-1 infected children
Nowak P, Karlsson Ac, Naver L, Bohlin Ab, Piasek A, Sönnerborg A
HIV medicine 2002;3(1):1-11

Broad spectrum of time of detection, primary symptoms and disease progression in infants with HIV-1 infection
Naver L, Ehrnst A, Belfrage E, Blomberg J, Christensson B, Forsgren M, et al
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES 2001;20(3):159-66

Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting
Euroguidelines Grp Hiv Resistance, Miller V, Vandamme Am, Loveday C, Staszewski S, Lundgren J, et al
AIDS 2001;15(3):309-20

Human immunodeficiency virus type 1 variability and long-term non-progression
Visco-comandini U, Aleman S, Yun Z, Sonnerborg A
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS 2001;15(3):299-303

Initiation of therapy during primary HIV type 1 infection results in a continuous decay of proviral DNA and a highly restricted viral evolution
Karlsson Ac, Birk M, Lindback S, Gaines H, Mittler Je, Sonnerborg A
AIDS RESEARCH AND HUMAN RETROVIRUSES 2001;17(5):409-16

Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy
Birk M, Svedhem V, Sonnerborg A
AIDS 2001;15(11):1359-68

Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up
Vandamme Am, Houyez F, Banhegyi D, Clotet B, De Schrijver G, De Smet Kal, et al
ANTIVIRAL THERAPY 2001;6(1):21-39

Management of infections caused by respiratory syncytial virus
Swedish Consensus Grp, Rastad Aa, Andersson J, Beermann B, Bohlin Ab, Brandt C, et al
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2001;33(5):323-8

Quantitative single cell methods that identify cytokine and chemokine expression in dendritic cells
Lore K, Spetz Al, Fehniger Te, Sonnerborg A, Landay Al, Andersson J
JOURNAL OF IMMUNOLOGICAL METHODS 2001;249(1-2):207-22

Recent origin of human immunodeficiency virus type 1 variants in resting CD4(+) T lymphocytes in untreated and suboptimally treated subjects
Karlsson Ac, Lindkvist A, Lindback S, Gaines H, Sonnerborg A
JOURNAL OF INFECTIOUS DISEASES 2001;184(11):1392-401

Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1
Maijgren-steffensson C, Sonnerborg A, Vahlne A, Britton S, Larsson S, Ahrlund-richter L
MOLECULAR THERAPY 2001;3(4):531-5

Antiretroviral therapy may improve sensory function in HIV-infected patients
Martin C, Solders G, Sonnerborg A, Hansson P
NEUROLOGY 2000;54(11):2120-7

Chronic hepatitis C - Swedish experts' meeting recommends combination treatment
Wejstal R, Fischler B, Glaumann H, Norkrans G, Reichard O, Sonnerborg A, et al
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2000;32(5):465-70

Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure
Karolinska Inst Primary Hiv Infect, Lindback S, Thorstensson R, Karlsson Ac, Von Sydow M, Flamholc L, et al
AIDS 2000;14(15):2333-9

High plasma levels of soluble Fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy
De Milito A, Hejdeman B, Albert J, Aleman S, Sonnerborg A, Zazzi M, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 2000;16(14):1379-84

[Mother-to-child transmission of HIV infections. Antiviral agents and Cesarean section reduce the risk of transmission]
Bohlin Ab, Lindgren S, Lidman K, Sönnerborg A
Lakartidningen 2000;97(28-29):3275-9

Proviral HIV-1 dynamics and evolution in patients receiving efficient long-term antiretroviral combination therapy
Birk M, Aleman S, Visco-comandini U, Sönnerborg A
HIV medicine 2000;1(4):205-11

Rapid and simple determination of indinavir in serum, urine, and cerebrospinal fluid using high-performance liquid chromatography
Svensson Jo, Sonnerborg A, Stahle L
THERAPEUTIC DRUG MONITORING 2000;22(5):626-9

Switching antiretroviral therapy from an enzyme-inducing drug
Gyllensten K, Sonnerborg A, Stahle L
THERAPEUTIC DRUG MONITORING 2000;22(5):637-8

The Quest Trial, a paradigm of HIV collaborative research
Goh Le, Mcdade H, Kinloch S, Perrin L, Cooper D, Phillips A, et al
NATURE MEDICINE 2000;6(11):1194-

Variability and immunogenicity of human immunodeficiency virus type 1 p24 gene quasispecies
Iroegbu J, Birk M, Lazdina U, Sonnerborg A, Sallberg M
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY 2000;7(3):377-83

Viral dynamics in primary HIV-1 infection
Karolinska Institutet Primary Hiv, Lindback S, Karlsson Ac, Mittler J, Blaxhult A, Carlsson M, et al
AIDS 2000;14(15):2283-91

DNA sequence of the long terminal repeat of human immunodeficiency virus type I subtype A through G
Naghavi Mh, Salminen Mo, Sonnerborg A, Vahlne A
AIDS RESEARCH AND HUMAN RETROVIRUSES 1999;15(5):485-8

HIV-1 exposed dendritic cells show increased pro-inflammatory cytokine production but reduced IL-1ra following lipopolysaccharide stimulation
Lore K, Sonnerborg A, Olsson J, Patterson Bk, Fehniger Te, Perbeck L, et al
AIDS 1999;13(15):2013-21

HIV viral load and response to antileishmanial chemotherapy in co-infected patients
Berhe N, Wolday D, Hailu A, Abraham Y, Ali A, Gebre-michael T, et al
AIDS 1999;13(14):1921-5

Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system
Martin C, Sonnerborg A, Svensson Jo, Stahle L
AIDS 1999;13(10):1227-32

Kinetics of beta-chemokine levels during anti-HIV therapy
Aleman S, Pehrson P, Sonnerborg A
ANTIVIRAL THERAPY 1999;4(2):109-15

Limited humoral immunity in hepatitis C virus infection
Chen M, Sallberg M, Sonnerborg A, Weiland O, Mattsson L, Jin L, et al
GASTROENTEROLOGY 1999;116(1):135-43

Longitudinal quantification of human immunodeficiency virus type 1 DNA and RNA in long-term nonprogressors
Brostrom C, Visco-comandini U, Yun Zb, Sonnerborg A
JOURNAL OF INFECTIOUS DISEASES 1999;179(6):1542-8

Long-term effects of antiretroviral combination therapy on HIV type 1 DNA levels
Aleman S, Visco-comandini U, Lore K, Sonnerborg A
AIDS RESEARCH AND HUMAN RETROVIRUSES 1999;15(14):1249-54

Long terminal repeat promoter/enhancer activity of different subtypes of HIV type 1
Naghavi Mh, Schwartz S, Sonnerborg A, Vahlne A
AIDS RESEARCH AND HUMAN RETROVIRUSES 1999;15(14):1293-303

Long-term pattern of HIV-1 RNA load in perinatally infected children
Naver L, Ehrnst A, Belfrage E, Sonnerborg A, Lidin-janson G, Christensson B, et al
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 1999;31(4):337-43

No association of HIV type 1 long terminal repeat sequence pattern with long-term nonprogression and in vivo viral replication levels in European subjects
Visco-comandini U, Yun Zb, Vahlne A, Sonnerborg A
AIDS RESEARCH AND HUMAN RETROVIRUSES 1999;15(7):609-17

Pain in ambulatory HIV-infected patients with and without intravenous drug use
Martin C, Pehrsson P, Osterberg A, Sonnerborg A, Hansson P
EUROPEAN JOURNAL OF PAIN 1999;3(2):157-164

Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection
Andersson J, Behbahani H, Lieberman J, Connick E, Landay A, Patterson B, et al
AIDS 1999;13(11):1295-303

Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients
Bjorndal A, Sonnerborg A, Tscherning C, Albert J, Fenyo Em
AIDS RESEARCH AND HUMAN RETROVIRUSES 1999;15(7):647-53

Reappearance of founder virus sequence in human immunodeficiency virus type 1-infected patients
Karlsson Ac, Gaines H, Sallberg M, Lindback S, Sonnerborg A
JOURNAL OF VIROLOGY 1999;73(7):6191-6

[Recommendations from a Swedish meeting of experts. Hepatitis C is to be treated with the combination of interferon and ribavirin]
Wejstål R, Fischler B, Glaumann H, Norkrans G, Reichard O, Sönnerborg A, et al
Lakartidningen 1999;96(44):4795-8

Relation between GB virus C/hepatitis G virus and fulminant hepatic failure may be secondary to treatment with contaminated blood and/or blood products
Halasz R, Barkholt L, Lara C, Hultgren C, Ando Y, Broome U, et al
GUT 1999;44(2):274-8

Similar HIV-1 subtype A V3 loop sequences are found in dual HIV-1/HIV-2 and HIV-1-only seropositives in Ghana
Sagoe Kwc, Britton S, Mingle Jaa, Affram K, Djokoto A, Sonnerborg A
AIDS RESEARCH AND HUMAN RETROVIRUSES 1999;15(8):775-9

The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination
Carlsson T, Struve J, Sonnerborg A, Weiland O
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 1999;31(1):93-5

Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults
Abacavir Phase 2 Clin Team, Saag Ms, Sonnerborg A, Torres Ra, Lancaster D, Gazzard Bg, et al
AIDS 1998;12(16):F203-9

Cerebrospinal fluid mononuclear cell counts influence CSF HIV-1 RNA levels
Martin C, Albert J, Hansson P, Pehrsson Po, Link H, Sonnerborg A
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 1998;17(3):214-9

Characterization of the viral population during primary HIV-1 infection
Karlsson Ac, Lindback S, Gaines H, Sonnerborg A
AIDS 1998;12(8):839-47

Coexisting members of HIV-1 p17 gene quasispecies represent proteins with distinct antigenicity and immunogenicity
Birk M, Flock Ji, Sonnerborg A, Sallberg M
AIDS 1998;12(15):1973-81

Combination treatment for hepatitis C can be hazardous in patients co-infected with HIV
Schvarcz R, Moberg L, Sonnerborg A
ANTIVIRAL THERAPY 1998;3(4):233-4

Comparison of 3 quantitative HCV RNA assays - Accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C
Reichard O, Norkrans G, Fryden A, Braconier Jh, Sonnerborg A, Weiland O
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 1998;30(5):441-6

Cooperative oligonucleotides mediating direct capture of hepatitis C virus RNA from serum
O'meara D, Yun Zb, Sonnerborg A, Lundeberg J
JOURNAL OF CLINICAL MICROBIOLOGY 1998;36(9):2454-9

Detection of hepatitis G virus GB virus C after allogeneic bone marrow transplantation
Ljungman P, Halasz R, Hagglund H, Sonnerborg A, Ringden O
BONE MARROW TRANSPLANTATION 1998;22(5):499-501

Detection of hepatitis G virus RNA in persons with and without known risk factors for blood-borne viral infections in Sweden and Honduras
Lara C, Halasz R, Sonnerborg A, Sallberg M
JOURNAL OF CLINICAL MICROBIOLOGY 1998;36(1):255-7

Distribution of the CCR5 gene 32 base pair deletion and SDF1-3 ' A variant in healthy individuals from different populations
Magierowska M, Lepage V, Boubnova L, Carcassi C, De Juan D, Djoulah S, et al
IMMUNOGENETICS 1998;48(6):417-9

Full-length sequence of human immunodeficiency virus type 1 subtype A, recombined with subtype C in the env V3 domain
Sherefa K, Johansson B, Salminen M, Sonnerborg A
AIDS RESEARCH AND HUMAN RETROVIRUSES 1998;14(3):289-92

HIV-1 nef mutations and clinical long-term nonprogression. A molecular epidemiology study
Visco-comandini U, Yun Z, Paganelli R, Orlandi P, Salotti A, Johansson B, et al
Journal of human virology 1998;1(5):320-7

Human and murine antibody recognition is focused on the ATPase/helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein
Chen M, Sallberg M, Sonnerborg A, Jin L, Birkett A, Peterson D, et al
HEPATOLOGY 1998;28(1):219-24

Immunocytochemical detection of cytokines and chemokines in Langerhans cells and in vitro derived dendritic cells
Lore K, Sonnerborg A, Spetz Al, Andersson U, Andersson J
JOURNAL OF IMMUNOLOGICAL METHODS 1998;214(1-2):97-111

Immunocytochemical detection of cytokines and chemokines in Langerhans cells and in vitro derived dendritic cells (vol 214, pg 97, 1998)
Lore K, Sonnerborg A, Spetz Al, Andersson U, Andersson J
JOURNAL OF IMMUNOLOGICAL METHODS 1998;218(1-2):173-87

Low relative frequencies of CD26(+) CD4(+) cells in long-term nonprogressing human immunodeficiency virus type 1-infected subjects
Brostrom C, Sonnerborg A, Lindback S, Gaines H
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY 1998;5(5):662-6

Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries
Schmit Jc, Van Laethem K, Ruiz L, Hermans P, Sprecher S, Sonnerborg A, et al
AIDS 1998;12(15):2007-15

Nonsynonymous mutations within the human immunodeficiency virus type 1 p17 gene are clustered to sequences binding to the host human leukocyte antigen class I molecules
Birk M, Vahlne A, Sonnerborg A, Sallberg M
AIDS RESEARCH AND HUMAN RETROVIRUSES 1998;14(3):241-8

Pronounced anti-HIV-1 activity of foscarnet in patients without cytomegalovirus infection
Bergdahl S, Jacobsson B, Moberg L, Sonnerborg A
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 1998;18(1):51-3

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C
Swedish Study Group, Reichard O, Norkrans G, Fryden A, Braconier Jh, Sonnerborg A, et al
LANCET 1998;351(9096):83-7

[Treatment of HIV infections--an update. The easy work is done--the difficult is still to be done]
Sönnerborg A, Pehrsson P
Lakartidningen 1998;95(42):4562-4

Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment
Odeberg J, Yun Zb, Sonnerborg A, Weiland O, Lundeberg J
JOURNAL OF MEDICAL VIROLOGY 1998;56(1):33-8

Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients
Birk M, Sonnerborg A
AIDS 1998;12(18):2369-75

Antibody production against hepatitis C virus core and nonstructural 3 proteins is highly sensitive to deficits in T-cell function
Ando Y, Sonnerborg A, Barkholt L, Birkett A, Ericzon Bg, Sallberg M
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY 1997;4(1):104-6

Apoptosis of CD4(+) and CD19(+) cells during human immunodeficiency virus type 1 infection - correlation with clinical progression, viral load, and loss of humoral immunity
Samuelsson A, Brostrom C, Vandijk N, Sonnerborg A, Chiodi F
VIROLOGY 1997;238(2):180-8

Cerebrospinal fluid analyses in HIV patients: a longitudinal study through six years
Pirskanen R, Samuelsson K, Sonnerborg A, Waldenlind L, Sandstrom E
EUROPEAN JOURNAL OF NEUROLOGY 1997;4(6):576-585

Detection of hepatitis G virus (GB virus C) RNA in human saliva
Chen M, Sonnerborg A, Johansson B, Sallberg M
JOURNAL OF CLINICAL MICROBIOLOGY 1997;35(4):973-5

Dynamic analysis of hepatitis C virus polymorphism in patients with orthotopic liver transplantation
Yun Zb, Barkholt L, Sonnerborg A
TRANSPLANTATION 1997;64(1):170-2

Dynamics of the HIV-1 subtype distribution in the Swedish HIV-1 epidemic during the period 1980 to 1993
Sonnerborg A, Durdevic S, Giesecke J, Sallberg M
AIDS RESEARCH AND HUMAN RETROVIRUSES 1997;13(4):343-5

Genetic evidence for mother-to-infant transmission of hepatitis G virus
Fischler B, Lara C, Chen M, Sonnerborg A, Nemeth A, Sallberg M
JOURNAL OF INFECTIOUS DISEASES 1997;176(1):281-5

Genotyping of hepatitis C virus performed by type-specific PCR in comparison to nucleotide sequencing of NS5 and core regions
Yun Z, Johansson B, Weiland O, Sonnerborg A
RESEARCH IN VIROLOGY 1997;148(3):233-7

[Hepatitis GBV isolated in acute liver failure. Successful outcome after liver transplantation]
Broomé U, Ericzon Bg, Eleborg L, Stål P, Oksanen A, Sönnerborg A
Lakartidningen 1997;94(40):3519-20

HIV-1 subtype C epidemic in Ethiopia
Sonnerborg A, Sherefa K
AIDS 1997;11(15):1897-

Indinavir in cerebrospinal fluid of HIV-1-infected patients
Stahle L, Martin C, Svensson Jo, Sonnerborg A
LANCET 1997;350(9094):1823-

[Measurement of HIV-RNA in blood is of great predictive value]
Sönnerborg A
Lakartidningen 1997;94(17):1589-90

Nosocomial transmission of hepatitis C virus
Schvarcz R, Johansson B, Nystrom B, Sonnerborg A
INFECTION 1997;25(2):74-7

Prevalence and risk factors for HTLV-II infection in 913 injecting drug users in Stockholm, 1994
Krook A, Albert J, Andersson S, Biberfeld G, Blomberg J, Eklund I, et al
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 1997;15(5):381-6

Progressive B cell apoptosis and expression of Fas ligand during human immunodeficiency virus type 1 infection
Samuelsson A, Sonnerborg A, Heuts N, Coster J, Chiodi F
AIDS RESEARCH AND HUMAN RETROVIRUSES 1997;13(12):1031-8

Quantification of HIV-1 proviral DNA from peripheral blood mononuclear cells using a high throughput four-competitor competitive PCR
Comandini Uv, Sonnerborg A, Vahlne A, Yun Zb
JOURNAL OF VIROLOGICAL METHODS 1997;69(1-2):171-80

Subtype-specific problems with quantification of plasma HIV-1 RNA
Alaeus A, Lidman K, Sonnerborg A, Albert J
AIDS 1997;11(7):859-65

Subtyping of human immunodeficiency virus type 1 strains by using antibodies specific for the third variable domain (V3) of gp120, results may be affected by divergent V3 sequences
Sherefa K, Sallberg M, Johansson B, Salminen M, Sonnerborg A
JOURNAL OF CLINICAL MICROBIOLOGY 1997;35(9):2419-21

The Honduran human immunodeficiency virus type 1 (HIV-1) epidemic is dominated by HIV-1 subtype B as determined by V3 domain sero- and genotyping
Lara C, Sallberg M, Johansson B, Derivera Il, Sonnerborg A
JOURNAL OF CLINICAL MICROBIOLOGY 1997;35(3):783-4

Variation of hepatitis C virus hypervariable region 1 in immunocompromised patients
Odeberg J, Yun Zb, Sonnerborg A, Bjoro K, Uhlen M, Lundeberg J
JOURNAL OF INFECTIOUS DISEASES 1997;175(4):938-43

A novel ribozyme target site located in the HIV-1 Nef open reading frame
Larsson S, Hotchkiss G, Su J, Kebede T, Andang M, Nyholm T, et al
VIROLOGY 1996;219(1):161-9

Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences
Yun Ab, Lara C, Johansson B, Derivera Il, Sonnerborg A
JOURNAL OF MEDICAL VIROLOGY 1996;49(3):155-60

Effect of N-acetylcysteine(NAC) treatment on HIV-1 infection: A double blind placebo controlled trial
Akerlund B, Jarstrand C, Lindeke B, Sonnerborg A, Akerblad Ac, Rasool O
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 1996;50(6):457-61

Full-length sequence of an Ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C
Salminen Mo, Johansson B, Sonnerborg A, Ayehunie S, Gotte D, Leinikki P, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 1996;12(14):1329-39

[News about HIV. Combination therapy with new drugs gives hope]
Sönnerborg A, Julander I
Lakartidningen 1996;93(6):451-2

Restriction of hepatitis C virus heterogeneity during prolonged interferon-alpha therapy in relation to changes in virus load
Yun Zb, Odeberg J, Lundeberg J, Weiland O, Uhlen M, Sonnerborg A
JOURNAL OF INFECTIOUS DISEASES 1996;173(4):992-6

Site-directed serology of HIV-1 subtype B infection: Relation between virus specific antibody levels and disease progression
Brostrom C, Sonnerborg A, Kim S, Sallberg M
CLINICAL AND EXPERIMENTAL IMMUNOLOGY 1996;106(1):35-9

2-YEAR BIOCHEMICAL, VIROLOGICAL, AND HISTOLOGICAL FOLLOW-UP IN PATIENTS WITH CHRONIC HEPATITIS-C RESPONDING IN A SUSTAINED FASHION TO INTERFERON ALFA-2B TREATMENT
Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A, et al
HEPATOLOGY 1995;21(4):918-22

Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience
Schvarcz R, Ando Y, Sonnerborg A, Weiland O
JOURNAL OF HEPATOLOGY 1995;:17-21

COMBINED TREATMENT WITH INTERFERON-ALPHA-2B AND RIBAVIRIN FOR CHRONIC HEPATITIS-C IN PATIENTS WITH A PREVIOUS NONRESPONSE OR NONSUSTAINED RESPONSE TO INTERFERON ALONE
Schvarcz R, Yun Zb, Sonnerborg A, Weiland O
JOURNAL OF MEDICAL VIROLOGY 1995;46(1):43-7

DETECTION OF HEPATITIS-C VIRUS-RNA IN THE CELL FRACTION OF SALIVA BEFORE AND AFTER ORAL-SURGERY
Chen M, Yun Zb, Sallberg M, Schvarcz R, Bergquist I, Berglund Hb, et al
JOURNAL OF MEDICAL VIROLOGY 1995;45(2):223-6

DISTINGUISHING ACUTE FROM SYMPTOMATIC CHRONIC HEPATITIS-C VIRUS (HCV) INFECTION BY SITE-DIRECTED SEROLOGY OF THE HCV STRUCTURAL PROTEINS
Zhang Zx, Chen M, Sonnerborg A, Weiland O, Sallberg M
JOURNAL OF INFECTIOUS DISEASES 1995;171(5):1356-9

DYNAMIC ANALYSIS OF HETEROGENEOUS HEPATITIS-C VIRUS POPULATIONS BY DIRECT SOLID-PHASE SEQUENCING
Odeberg J, Yun Zb, Sonnerborg A, Uhlen M, Lundeberg J
JOURNAL OF CLINICAL MICROBIOLOGY 1995;33(7):1870-4

Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection
Weiland O, Chen M, Lindh G, Mattsson L, Schvarcz R, Sönnerborg A, et al
Scandinavian journal of infectious diseases 1995;27(5):319-24

Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection
Weiland O, Chen M, Lindh G, Mattsson L, Schvarcz R, Sönnerborg A, et al
Scandinavian journal of infectious diseases 1995;27(4):319-24

EFFICACY OF HUMAN-LEUKOCYTE ALPHA-INTERFERON TREATMENT FOR CHRONIC HEPATITIS-C VIRUS-INFECTION
Weiland O, Chen M, Lindh G, Mattsson L, Schvarcz R, Sonnerborg A, et al
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 1995;27(4):319-324

ELEVATED LEVELS OF CIRCULATING TUMOR-NECROSIS-FACTOR-ALPHA IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED AFRICANS LIVING IN SWEDEN
Sonnerborg A, Ayehunie S, Julander I
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY 1995;2(1):118-9

EVALUATION OF A MULTIPLE PEPTIDE ASSAY FOR TYPING OF ANTIBODIES TO THE HEPATITIS-C VIRUS - RELATION TO GENOMIC TYPING BY THE POLYMERASE CHAIN-REACTION
Zhang Zx, Yun Zb, Chen M, Sonnerborg A, Sallberg M
JOURNAL OF MEDICAL VIROLOGY 1995;45(1):50-5

HIV-INFECTION AND MATERNAL OUTCOME OF PREGNANCY IN MOZAMBICAN WOMEN - A CASE-CONTROL STUDY
Bergstrom S, Sonnerborg A, Osman Nb, Libombo A
GENITOURINARY MEDICINE 1995;71(5):323-4

HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED PATIENTS WITH NO DISEASE PROGRESSION DISPLAY HIGH-AVIDITY ANTIBODY-PRODUCTION TO AUTOLOGOUS V3 SEQUENCES
Brostrom C, Sonnerborg A, Sallberg M
JOURNAL OF INFECTIOUS DISEASES 1995;171(2):509-11

LEVELS OF HEPATITIS-C VIRUS (HCV) RNA IN SERUM AND THEIR RELATIONSHIP TO LEVELS OF IMMUNOGLOBULIN-M AND IMMUNOGLOBULIN-G ANTIBODIES AGAINST HCV CORE PROTEIN
Chen M, Sonnerborg A, Sallberg M
JOURNAL OF CLINICAL MICROBIOLOGY 1995;33(3):778-80

LONG-TERM EFFECTS OF HEPATITIS-C VIRUS-INFECTION IN ALLOGENEIC BONE-MARROW TRANSPLANT RECIPIENTS
Ljungman P, Johansson N, Aschan J, Glaumann H, Lonnqvist B, Ringden O, et al
BLOOD 1995;86(4):1614-8

MULTIPLE ENHANCER MOTIFS IN HIV TYPE-1 STRAINS FROM ETHIOPIA
Johansson B, Sherefa K, Sonnerborg A
AIDS RESEARCH AND HUMAN RETROVIRUSES 1995;11(6):761-4

[Parvovirus B19 infection in different shapes. But more laboratories have refined the diagnostic methods]
Jorup C, Gyllensten K, Persson A, Forsgren M, Sönnerborg A
Lakartidningen 1995;92(46):4331-4

PREVENTION OF NOSOCOMIAL TRANSMISSION OF HEPATITIS-C VIRUS
Schvarcz R, Nystrom B, Oksanen A, Sonnerborg A
LANCET 1995;346(8968):190-

TRANSMISSION OF HEPATITIS-C VIRUS BY TRANSFUSION IN OREBRO COUNTY, SWEDEN, 1990-1992
Norda R, Duberg As, Sonnerborg A, Olcen P
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 1995;27(5):449-52

Show all publications